BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,892 | -18.0% | 57,175 | -1.6% | 0.03% | -13.2% |
| Q2 2023 | $4,744 | +11.1% | 58,116 | +1.0% | 0.04% | +5.6% |
| Q1 2023 | $4,270 | -15.2% | 57,553 | -5.2% | 0.04% | -20.0% |
| Q4 2022 | $5,034 | -99.9% | 60,738 | +307.0% | 0.04% | +9.8% |
| Q3 2022 | $4,239,000 | -17.8% | 14,925 | +0.4% | 0.04% | -14.6% |
| Q2 2022 | $5,155,000 | -23.4% | 14,872 | -4.3% | 0.05% | -7.7% |
| Q1 2022 | $6,729,000 | -57.4% | 15,540 | -49.1% | 0.05% | -10.3% |
| Q4 2021 | $15,786,000 | +133.1% | 30,514 | +118.4% | 0.06% | +1.8% |
| Q3 2021 | $6,771,000 | -51.7% | 13,973 | -55.2% | 0.06% | -49.1% |
| Q2 2021 | $14,030,000 | +403.6% | 31,160 | +327.2% | 0.11% | +7.7% |
| Q1 2021 | $2,786,000 | +11.8% | 7,294 | -7.0% | 0.10% | +10.6% |
| Q4 2020 | $2,491,000 | +28.7% | 7,845 | +0.4% | 0.09% | +11.9% |
| Q3 2020 | $1,936,000 | -8.6% | 7,816 | -2.6% | 0.08% | -14.3% |
| Q2 2020 | $2,119,000 | +9.1% | 8,023 | -21.7% | 0.10% | +108.5% |
| Q1 2020 | $1,942,000 | -14.9% | 10,244 | -1.5% | 0.05% | +11.9% |
| Q4 2019 | $2,283,000 | +18.4% | 10,400 | +5.6% | 0.04% | +2.4% |
| Q3 2019 | $1,928,000 | +6.9% | 9,852 | +13.9% | 0.04% | -2.4% |
| Q2 2019 | $1,803,000 | +2.9% | 8,646 | -2.1% | 0.04% | 0.0% |
| Q1 2019 | $1,753,000 | +39.1% | 8,828 | +1.4% | 0.04% | +16.7% |
| Q4 2018 | $1,260,000 | +12.5% | 8,706 | +58.6% | 0.04% | +28.6% |
| Q3 2018 | $1,120,000 | -16.5% | 5,488 | -39.5% | 0.03% | -15.2% |
| Q2 2018 | $1,342,000 | +7.3% | 9,072 | +9.6% | 0.03% | 0.0% |
| Q1 2018 | $1,251,000 | +24.2% | 8,280 | +6.5% | 0.03% | +22.2% |
| Q4 2017 | $1,007,000 | +13.0% | 7,772 | +5.4% | 0.03% | -3.6% |
| Q3 2017 | $891,000 | +2.2% | 7,373 | -0.6% | 0.03% | -3.4% |
| Q2 2017 | $872,000 | +45.1% | 7,420 | +25.4% | 0.03% | -3.3% |
| Q1 2017 | $601,000 | -17.8% | 5,916 | -16.7% | 0.03% | -9.1% |
| Q4 2016 | $731,000 | +4.0% | 7,105 | +10.7% | 0.03% | -19.5% |
| Q3 2016 | $703,000 | -2.0% | 6,419 | -0.1% | 0.04% | 0.0% |
| Q2 2016 | $717,000 | +67.9% | 6,423 | +42.0% | 0.04% | -2.4% |
| Q1 2016 | $427,000 | +14.2% | 4,522 | +8.9% | 0.04% | -8.7% |
| Q4 2015 | $374,000 | -9.0% | 4,153 | -6.5% | 0.05% | +7.0% |
| Q3 2015 | $411,000 | -4.9% | 4,442 | +1.3% | 0.04% | +2.4% |
| Q2 2015 | $432,000 | +60.6% | 4,383 | +63.2% | 0.04% | +27.3% |
| Q1 2015 | $269,000 | +14.5% | 2,686 | +5.7% | 0.03% | -10.8% |
| Q4 2014 | $235,000 | -0.4% | 2,541 | +0.9% | 0.04% | +5.7% |
| Q3 2014 | $236,000 | – | 2,519 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |